Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. Issue 185 (January 2020)

• Record Type: Journal Article
• Authors: Palandri, Francesca; Santoro, Cristina; Carpenedo, Monica; Cantoni, Silvia; Barcellini, Wilma; Carli, Giuseppe; Carrai, Valentina; Rossi, Elena; Rivolti, Elena; Lucchesi, Alessandro; Rotondo, Francesco; Baldacci, Erminia; Auteri, Giuseppe; Sutto, Emanuele; Di Pietro, Christian; Catani, Lucia; Bartoletti, Daniela; De Stefano, Valerio; Ruggeri, Marco; Mazzucconi, Maria Gabriella; Cavo, Michele; Rodeghiero, Francesco; Vianelli, Nicola
• Is Part Of: Thrombosis research. Issue 185(2020)
• Page Start: 88
• Page End: 95
• Publication Date: 2020-01
• Subjects: ITP -- Immune thrombocytopenia -- Elderly -- TPO-receptor agonists -- Toxicity; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2019.11.026
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Introduction: Primary Immune thrombocytopenia (ITP) in the elderly is a major clinical challenge which is increasingly frequent due to global ageing population. Materials and methods: To describe baseline ITP features, management, and outcome, a centralized electronic database was established, including data of 451 patients aged ≥60 years that were treated from 2000 onwards and were observed for ≥1 year (total observation of 2704 patient-years). Results: At ITP diagnosis, median age was 71.1 years (age ≥ 75: 42.8%); 237 (53.9%) patients presented with haemorrhages (grade ≥ 3: 7.5%). First-line therapy included prednisone (82.9%), dexamethasone (14.6%), thrombopoietin-receptor agonists (TRAs, 1.3%), and oral immunosuppressive agents (1.1%). Prednisone starting dose ≥1 mg/kg/d ( p = .01) and dexamethasone 40 mg/d ( p < .001) were mainly reserved to patients aged 60–74, who were more treated with rituximab (RTX, p = .02) and splenectomy ( p = .03) second-line. Overall response rates to first and second-line therapies were 83.8% and 84.5%, respectively, regardless of age and treatment type/dose. A total of 178 haemorrhages in 101 patients (grade ≥ 3: n. 52, 29.2%; intracranial in 6 patients), 49 thromboses in 43 patients (grade ≥ 3: n. 26, 53.1%) and 115 infections in 94 patients (grade ≥ 3: n. 23, 20%) were observed during follow-up. Incidence rates of complications per 100 patient-years were: 4.5 (haemorrhages, grade ≥ 3: 1.7), 1.7 (thromboses, grade ≥ 3: 0.9), and 3.9 (infections, grade ≥ 3: 0.7). TRAs use were associated with reduced risk of bleeding and infections, while cardiovascular risk factors (particularly, diabetes) significantly predicted thromboses and infections. Conclusions: Age-adapted treatment strategies are required in elderly and very elderly patients. Highlights: Very old age significantly influences treatment strategy in ITP. Responses and disease complications are comparable in elderly and very elderly. TRAs use may reduce risk of bleedings and infections in the elderly. History of diabetes and thrombosis, but not TRAs use, increases thrombotic risk.